Arbutus Total Liab vs Accounts Payable Analysis

ABUS Stock

USD 2.73 0.01 0.37%

Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Total Liab and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Total Liab account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Arbutus Biopharma's Total Liab and Accounts Payable is 0.4. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Total Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Arbutus Biopharma Corp are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Liab i.e., Arbutus Biopharma's Total Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Accounts Payable

An accounting item on the balance sheet that represents Arbutus Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Arbutus Biopharma Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

At this time, Arbutus Biopharma's Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.32 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

Arbutus Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Other Liab	Net Tangible Assets
Total Assets		-0.17	0.08	1.0	0.14	-0.73	-0.04	0.76	0.97	0.4	0.75	-0.04	0.32	0.1	0.12	0.97	-0.16	-0.26	0.97	0.01	0.74	-0.22	0.2	0.63	0.97	0.9
Other Current Liab	-0.17		0.74	-0.17	-0.2	0.23	-0.19	-0.26	-0.23	0.0	0.05	0.18	0.16	0.37	0.31	-0.28	0.19	0.16	-0.14	0.03	0.06	0.08	-0.03	-0.32	-0.24	-0.03
Total Current Liabilities	0.08	0.74		0.05	0.03	0.07	-0.61	-0.01	-0.09	-0.26	0.4	0.38	0.66	0.81	0.64	0.0	0.49	0.04	0.16	0.43	0.4	-0.11	0.02	-0.13	0.02	0.24
Total Stockholder Equity	1.0	-0.17	0.05		0.14	-0.74	-0.03	0.77	0.96	0.43	0.75	-0.04	0.31	0.09	0.11	0.95	-0.15	-0.27	0.95	0.01	0.74	-0.23	0.18	0.62	0.95	0.9
Property Plant And Equipment Net	0.14	-0.2	0.03	0.14		0.14	-0.67	-0.1	-0.01	0.07	0.46	0.11	0.56	0.34	0.62	0.06	0.45	-0.12	0.1	0.61	0.47	-0.18	-0.44	0.01	0.02	-0.13
Net Debt	-0.73	0.23	0.07	-0.74	0.14		-0.17	-0.99	-0.7	-0.24	-0.59	-0.24	-0.05	0.12	0.33	-0.69	0.13	0.28	-0.66	0.31	-0.58	0.24	-0.2	-0.37	-0.7	-0.67
Retained Earnings	-0.04	-0.19	-0.61	-0.03	-0.67	-0.17		0.09	0.17	0.39	-0.5	-0.51	-0.93	-0.9	-0.83	0.06	-0.79	-0.07	-0.06	-0.84	-0.51	0.1	0.41	0.3	0.04	-0.01
Cash	0.76	-0.26	-0.01	0.77	-0.1	-0.99	0.09		0.72	0.23	0.63	0.23	0.14	-0.03	-0.25	0.73	-0.07	-0.29	0.7	-0.2	0.62	-0.27	0.24	0.42	0.73	0.72
Non Current Assets Total	0.97	-0.23	-0.09	0.96	-0.01	-0.7	0.17	0.72		0.42	0.56	-0.18	0.11	-0.08	-0.07	0.97	-0.36	-0.2	0.94	-0.14	0.55	-0.12	0.26	0.66	0.97	0.88
Non Currrent Assets Other	0.4	0.0	-0.26	0.43	0.07	-0.24	0.39	0.23	0.42		0.26	-0.57	-0.24	-0.41	-0.01	0.33	-0.33	-0.41	0.27	-0.22	0.25	-0.29	0.25	0.48	0.28	0.31
Cash And Short Term Investments	0.75	0.05	0.4	0.75	0.46	-0.59	-0.5	0.63	0.56	0.26		0.34	0.66	0.45	0.52	0.64	0.35	-0.34	0.73	0.28	1.0	-0.39	-0.04	0.37	0.63	0.64
Net Receivables	-0.04	0.18	0.38	-0.04	0.11	-0.24	-0.51	0.23	-0.18	-0.57	0.34		0.42	0.45	0.17	-0.15	0.67	0.11	-0.04	0.08	0.36	-0.03	-0.39	-0.4	-0.1	-0.07
Common Stock Total Equity	0.32	0.16	0.66	0.31	0.56	-0.05	-0.93	0.14	0.11	-0.24	0.66	0.42		0.93	0.82	0.23	0.7	-0.1	0.33	0.83	0.66	-0.25	-0.26	-0.07	0.25	0.34
Common Stock Shares Outstanding	0.1	0.37	0.81	0.09	0.34	0.12	-0.9	-0.03	-0.08	-0.41	0.45	0.45	0.93		0.78	0.02	0.7	0.05	0.15	0.8	0.45	-0.11	-0.25	-0.27	0.06	0.23
Short Term Investments	0.12	0.31	0.64	0.11	0.62	0.33	-0.83	-0.25	-0.07	-0.01	0.52	0.17	0.82	0.78		0.04	0.62	-0.1	0.17	0.76	0.53	-0.22	-0.24	-0.03	0.02	0.11
Non Current Liabilities Total	0.97	-0.28	0.0	0.95	0.06	-0.69	0.06	0.73	0.97	0.33	0.64	-0.15	0.23	0.02	0.04		-0.31	-0.24	0.98	-0.04	0.63	-0.17	0.29	0.69	0.99	0.88
Other Current Assets	-0.16	0.19	0.49	-0.15	0.45	0.13	-0.79	-0.07	-0.36	-0.33	0.35	0.67	0.7	0.7	0.62	-0.31		0.08	-0.2	0.64	0.37	-0.1	-0.24	-0.33	-0.3	-0.13
Other Stockholder Equity	-0.26	0.16	0.04	-0.27	-0.12	0.28	-0.07	-0.29	-0.2	-0.41	-0.34	0.11	-0.1	0.05	-0.1	-0.24	0.08		-0.21	0.01	-0.33	0.98	0.18	-0.32	-0.2	-0.19
Total Liab	0.97	-0.14	0.16	0.95	0.1	-0.66	-0.06	0.7	0.94	0.27	0.73	-0.04	0.33	0.15	0.17	0.98	-0.2	-0.21		0.01	0.72	-0.17	0.25	0.66	0.97	0.89
Property Plant And Equipment Gross	0.01	0.03	0.43	0.01	0.61	0.31	-0.84	-0.2	-0.14	-0.22	0.28	0.08	0.83	0.8	0.76	-0.04	0.64	0.01	0.01		0.28	-0.13	-0.2	-0.19	-0.03	0.03
Total Current Assets	0.74	0.06	0.4	0.74	0.47	-0.58	-0.51	0.62	0.55	0.25	1.0	0.36	0.66	0.45	0.53	0.63	0.37	-0.33	0.72	0.28		-0.39	-0.04	0.36	0.62	0.63
Common Stock	-0.22	0.08	-0.11	-0.23	-0.18	0.24	0.1	-0.27	-0.12	-0.29	-0.39	-0.03	-0.25	-0.11	-0.22	-0.17	-0.1	0.98	-0.17	-0.13	-0.39		0.21	-0.24	-0.15	-0.15
Short Long Term Debt Total	0.2	-0.03	0.02	0.18	-0.44	-0.2	0.41	0.24	0.26	0.25	-0.04	-0.39	-0.26	-0.25	-0.24	0.29	-0.24	0.18	0.25	-0.2	-0.04	0.21		0.63	0.25	0.34
Short Term Debt	0.63	-0.32	-0.13	0.62	0.01	-0.37	0.3	0.42	0.66	0.48	0.37	-0.4	-0.07	-0.27	-0.03	0.69	-0.33	-0.32	0.66	-0.19	0.36	-0.24	0.63		0.62	0.59
Other Liab	0.97	-0.24	0.02	0.95	0.02	-0.7	0.04	0.73	0.97	0.28	0.63	-0.1	0.25	0.06	0.02	0.99	-0.3	-0.2	0.97	-0.03	0.62	-0.15	0.25	0.62		0.89
Net Tangible Assets	0.9	-0.03	0.24	0.9	-0.13	-0.67	-0.01	0.72	0.88	0.31	0.64	-0.07	0.34	0.23	0.11	0.88	-0.13	-0.19	0.89	0.03	0.63	-0.15	0.34	0.59	0.89

Click cells to compare fundamentals

Arbutus Biopharma Account Relationship Matchups

Arbutus Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	105.5M	137.1M	204.5M	195.4M	144.4M	124.4M
Other Current Liab	253K	250K	26K	12.5M	7.0M	3.8M
Total Current Liabilities	7.8M	9.5M	11.2M	32.9M	22.5M	23.6M
Total Stockholder Equity	72.7M	102.0M	169.4M	136.9M	106.0M	93.5M
Property Plant And Equipment Net	11.4M	9.3M	8.1M	6.8M	6.1M	4.8M
Net Debt	(28.4M)	(49.3M)	(106.7M)	(28.6M)	(17.6M)	(18.4M)
Retained Earnings	(970.1M)	(1.0B)	(1.1B)	(1.2B)	(1.3B)	(1.2B)
Cash	31.8M	52.3M	109.3M	30.8M	26.3M	39.9M
Non Current Assets Total	11.7M	9.4M	43.8M	44.3M	12.4M	11.8M
Non Currrent Assets Other	293K	44K	61K	103K	92.7K	88.1K
Cash And Short Term Investments	90.8M	123.3M	155.3M	146.9M	126.0M	73.6M
Net Receivables	1.2M	4.4M	5.3M	4.2M	2.4M	1.8M
Common Stock Total Equity	898.5M	985.9M	1.3B	1.3B	1.5B	1.6B
Common Stock Shares Outstanding	57.1M	75.8M	106.2M	150.9M	166.0M	174.3M
Short Term Investments	59.0M	71.0M	46.0M	116.1M	99.7M	104.7M
Liabilities And Stockholders Equity	105.5M	137.1M	204.5M	195.4M	144.4M	124.4M
Non Current Liabilities Total	25.0M	25.6M	23.8M	25.7M	15.9M	25.0M
Other Current Assets	1.8M	3.1M	4.4M	2.9M	3.6M	3.8M
Other Stockholder Equity	55.2M	60.8M	65.5M	72.4M	81.3M	78.5M
Total Liab	32.8M	35.1M	35.0M	58.6M	38.4M	31.0M
Property Plant And Equipment Gross	11.4M	9.3M	8.1M	6.8M	18.0M	18.9M
Total Current Assets	93.8M	127.7M	160.7M	151.1M	132.0M	76.6M
Common Stock	898.5M	985.9M	1.3B	1.3B	1.3B	1.4B
Other Liab	21.9M	23.0M	21.6M	23.9M	27.5M	18.6M
Net Tangible Assets	(64.5M)	(47.4M)	169.4M	136.9M	157.4M	165.2M
Accounts Payable	2.4M	3.0M	3.2M	3.5M	3.2M	2.5M
Retained Earnings Total Equity	(970.1M)	(1.0B)	(1.1B)	(1.2B)	(1.1B)	(1.0B)
Preferred Stock Total Equity	49.8M	126.1M	137.3M	149.4M	171.8M	180.4M
Accumulated Other Comprehensive Income	(48.2M)	(48.2M)	(48.3M)	(50.5M)	(48.4M)	(46.0M)
Property Plant Equipment	8.7M	6.9M	6.0M	5.1M	5.8M	4.5M
Capital Surpluse	55.2M	60.8M	65.5M	72.4M	83.3M	53.5M

Pair Trading with Arbutus Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.

The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Arbutus Biopharma Corp is a strong investment it is important to analyze Arbutus Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arbutus Biopharma's future performance. For an informed investment choice regarding Arbutus Stock, refer to the following important reports:

How To Invest In Arbutus

Details

Is Arbutus Stock a good investment?

Details

What is Arbutus Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Arbutus Stock analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Revenue Per Share

0.109

Quarterly Revenue Growth

(0.66)

Return On Assets

(0.29)

Return On Equity

(0.60)

The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arbutus Total Liab vs Accounts Payable Analysis

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Liab

Accounts Payable

Arbutus Biopharma fundamental ratios Correlations

Arbutus Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arbutus Biopharma fundamental ratios Accounts

Pair Trading with Arbutus Biopharma

Complementary Tools for Arbutus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Liab	+ 0.99	Non Current Liabilities Total
Total Liab	+ 0.98	Non Current Liabilities Total
Common Stock	+ 0.98	Other Stockholder Equity
Non Current Assets Total	+ 0.97	Total Assets

Cash	- 0.99	Net Debt
Common Stock Total Equity	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.9	Retained Earnings
Property Plant And Equipment Gross	- 0.84	Retained Earnings
Short Term Investments	- 0.83	Retained Earnings
Other Current Assets	- 0.79	Retained Earnings